LRRK2 and Parkinson disease: In iPSC-derived NSCs containing a leucine-rich repeat kinase 2 (LRRK2) dominant mutation (G2019S) obtained from PD patients, deficiencies in clonal expansion and neuronal differentiation were observed after passage 16 (Liu et al., 2012).